Phage therapy of e coli infections
AssigneePherecydes Pharma
InventorsFLAVIE POUILLOT, HÉLÈNE BLOIS
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Claims18
1-21. (canceled)
An antibacterial composition comprising at least two distinct bacteriophages having lytic activity to an Escherichia coli (E. coli) strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 90% identity thereto.
A bacteriophage having lytic activity to an E. coli strain and having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 97% identity thereto.
A bacteriophage having lytic activity to a pathogenic E. coli strain, wherein the bacteriophage (i) is specific for E. coli (ii) is active against antibiotic-resistant E. coli strains, and (iii) has a productive lytic effect (PLE) below 15.
Dependencies are inferred from the claim text.